ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Takeda and Hoffmann-La Roche side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

TakedaHoffmann-La Roche
studies on the registry1,7542,744
open to participants now86115
phase 3 studies under way4495
reach primary completion within a year4779
programswith a study of their own in two years2580+25 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseTakedaHoffmann-La Roche
Phase 1

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 1

and 28 more — sign in to see them all

41%
Phase 2

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
Phase 3

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Hoffmann-La Roche28 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. cevostamabphase 3 · Nov 18 · NCT05646836
  2. emicizumabapproved, new study · Nov 19 · NCT05181618
  3. nivegacetorphase 2 · Nov 19 · NCT06402838
  4. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 3 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. mosunetuzumabphase 3 · Jul 31 · NCT05207670
  3. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Hoffmann-La Roche

New programs 5

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive
  • RO7568282phase 2 · first study · Aug 20 · Parkinson Disease

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 15 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionTakedaHoffmann-La Roche
Alzheimer Diseaseboth · compare here

Takeda in Alzheimer Disease: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Alzheimer Disease in search

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Primary Immunodeficiency Diseasesboth · compare here

Takeda in Primary Immunodeficiency Diseases: 4 programs

  1. Immunoglobulins, Intravenousapproved, new study
  2. TAK-664approved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Primary Immunodeficiency Diseases in search

Hoffmann-La Roche in Primary Immunodeficiency Diseases: 2 programs

  1. hyaluronidase (human recombinant)phase 2
  2. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Primary Immunodeficiency Diseases in search

Multiple Myelomaboth · compare here

Takeda in Multiple Myeloma: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Multiple Myeloma in search

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingboth · compare here

Takeda in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 4 programs

  1. TAK-411phase 2
  2. Immunoglobulins, Intravenousapproved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Hoffmann-La Roche in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 1 program

  1. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Crohn Diseaseboth · compare here

Takeda in Crohn Disease: 3 programs

  1. zasocitinibphase 3
  2. teduglutidephase 3
  3. ontamalimabphase 3

Their studies: Takeda’s studies of Crohn Disease in search

Hoffmann-La Roche in Crohn Disease: 1 program

  1. afimkibartphase 3

Their studies: Hoffmann-La Roche’s studies of Crohn Disease in search

Hemophilia Aboth · compare here

Takeda in Hemophilia A: 1 program

  1. antihemophilic factor, human recombinantapproved, new study

Their studies: Takeda’s studies of Hemophilia A in search

Hoffmann-La Roche in Hemophilia A: 3 programs

  1. zemocimigphase 3
  2. dirloctocogene samoparvovecphase 2
  3. emicizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Hemophilia A in search

Lupus Erythematosus, Systemicboth · compare here

Takeda in Lupus Erythematosus, Systemic: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Lupus Erythematosus, Systemic in search

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Prostatic Neoplasmsboth · compare here

Takeda in Prostatic Neoplasms: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Prostatic Neoplasms in search

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Renal Insufficiencyboth · compare here

Takeda in Renal Insufficiency: 1 program

  1. teduglutidephase 3

Their studies: Takeda’s studies of Renal Insufficiency in search

Hoffmann-La Roche in Renal Insufficiency: 3 programs

  1. petrelintidephase 3
  2. tifeglipronphase 2
  3. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Renal Insufficiency in search

Colitis, Ulcerativeboth · compare here

Takeda in Colitis, Ulcerative: 1 program

  1. ontamalimabphase 3

Their studies: Takeda’s studies of Colitis, Ulcerative in search

Hoffmann-La Roche in Colitis, Ulcerative: 2 programs

  1. afimkibartphase 3
  2. RO7837195phase 2

Their studies: Hoffmann-La Roche’s studies of Colitis, Ulcerative in search

Anemia, Sickle Cellboth · compare here

Takeda in Anemia, Sickle Cell: 1 program

  1. apadamtase alfaphase 3

Their studies: Takeda’s studies of Anemia, Sickle Cell in search

Hoffmann-La Roche in Anemia, Sickle Cell: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Anemia, Sickle Cell in search

Autoimmune Diseases of the Nervous Systemboth · compare here

Takeda in Autoimmune Diseases of the Nervous System: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Autoimmune Diseases of the Nervous System in search

Hoffmann-La Roche in Autoimmune Diseases of the Nervous System: 1 program

  1. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Autoimmune Diseases of the Nervous System in search

Show all 15

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Takeda 12 of 25 · Hoffmann-La Roche 40 of 80 programs (31 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25).